Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.04−0.20 (-2.16%)
Close on Nov 19, 2026Market cap $340.10MP/E –Yield –
Contineum Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Contineum Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2024 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $50.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $50.00M | – |
See a number that looks wrong?